Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00075829 · OUTCOME

Interval From First to Second Transplantation

Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) · Source last updated 2021-11-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
days
Interval / dispersion
Full Range
Time frame
Year 1

What was measured

Upon recovery from the first autograft, but at least 60 days (preferably between 60-120 days) after the first autograft, patients will receive a second transplant according to treatment assignments.

Analysis population: Patients that completed second transplant

Groups in this outcome

Auto-Auto Standard Risk

Tandem autologous transplant plus thalidomide/dexamethasone or observation for standard risk patients

Auto-Allo Standard Risk

Autologous transplant plus non-myeloablative allogeneic transplant for standard risk patients

Auto-Auto High Risk

Tandem autologous transplant plus thalidomide/dexamethasone or observation for high risk patients

Auto-Allo High Risk

Autologous transplant plus non-myeloablative allogeneic transplant for high risk patients

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Auto-Auto Standard Risk366
Auto-Allo Standard Risk156
Auto-Auto High Risk31
Auto-Allo High Risk29

Reported measurements

Source class 1
Values in days · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Auto-Auto Standard Risk98Not reported58193Not reported
Auto-Allo Standard Risk105Not reported61262Not reported
Auto-Auto High Risk101Not reported63155Not reported
Auto-Allo High Risk111Not reported61155Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        58
        upper Limit
        193
        value
        98
      2. group Id
        OG001
        lower Limit
        61
        upper Limit
        262
        value
        105
      3. group Id
        OG002
        lower Limit
        63
        upper Limit
        155
        value
        101
      4. group Id
        OG003
        lower Limit
        61
        upper Limit
        155
        value
        111
denoms
  1. counts
    1. group Id
      OG000
      value
      366
    2. group Id
      OG001
      value
      156
    3. group Id
      OG002
      value
      31
    4. group Id
      OG003
      value
      29
    units
    Participants
description
Upon recovery from the first autograft, but at least 60 days (preferably between 60-120 days) after the first autograft, patients will receive a second transplant according to treatment assignments.
dispersion Type
Full Range
groups
  1. description
    Tandem autologous transplant plus thalidomide/dexamethasone or observation for standard risk patients
    id
    OG000
    title
    Auto-Auto Standard Risk
  2. description
    Autologous transplant plus non-myeloablative allogeneic transplant for standard risk patients
    id
    OG001
    title
    Auto-Allo Standard Risk
  3. description
    Tandem autologous transplant plus thalidomide/dexamethasone or observation for high risk patients
    id
    OG002
    title
    Auto-Auto High Risk
  4. description
    Autologous transplant plus non-myeloablative allogeneic transplant for high risk patients
    id
    OG003
    title
    Auto-Allo High Risk
param Type
MEDIAN
population Description
Patients that completed second transplant
reporting Status
POSTED
time Frame
Year 1
title
Interval From First to Second Transplantation
type
SECONDARY
unit Of Measure
days

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice